Biocryst Pharmaceuticals (BCRX) Income towards Parent Company (2010 - 2026)

Biocryst Pharmaceuticals has reported Income towards Parent Company for 17 years, with the latest figure at -$721.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 2255762.5% year-over-year to -$721.8 million; the trailing twelve-month figure through Mar 2026 stood at -$458.0 million (down 756.52% YoY), and the FY2025 full-year result was $263.9 million, up 396.87% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$721.8 million, down from $245.8 million in the prior quarter.
• The five-year high for Income towards Parent Company was $245.8 million in Q4 2025, with the low at -$721.8 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$60.0 million across 5 years, with a median of -$36.1 million in 2023.
• Annual changes were most pronounced in 2025 — Income towards Parent Company surged 1017.5% — and 2026, when it tumbled 2255762.5%.
• Biocryst Pharmaceuticals' Income towards Parent Company stood at -$71.5 million in 2022, then increased by 13.71% to -$61.7 million in 2023, then surged by 56.59% to -$26.8 million in 2024, then surged by 1017.5% to $245.8 million in 2025, then tumbled by 393.6% to -$721.8 million in 2026.
• The last three Income towards Parent Company figures came in at -$721.8 million (Q1 2026), $245.8 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.